Inovio Pharmaceuticals, Inc. (INO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 7 | 2 | 10 | 1 | 0 | 0 | - | - |
| Operating profit | $m | -87 | - | ||||||
| Net profit | $m | -166 | -304 | -280 | -135 | -107 | -85 | - | -36 |
| EPS reported | $ | -1.81 | - | ||||||
| Operating cashflow per share | $ | -1.89 | - | ||||||
| Capex per share | $ | 0.01 | - | ||||||
| FCF per share | $ | -1.90 | - | ||||||
| Free cash flow | $m | -89 | - | ||||||
| Net debt | $m | -59 | - | ||||||
| Book value equity | $m | 24 | - | ||||||
| Book value per share | $ | 0.51 | - | ||||||
| Number of shares | m | 46.89 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.39 | - | ||||||
| P/S LTM | x | 1,248.52 | - | ||||||
| P/FCF LTM | x | -0.92 | - | ||||||
| EV/EBITDA LTM | x | -0.57 | - | ||||||
| EV/Sales LTM | x | 714.34 | - | ||||||
| Earnings Yield LTM | % | -1.04% | - | ||||||
| FCF Yield | % | -108.99% | - | ||||||
| Quality | |||||||||
| ROE | % | -352.53% | - | ||||||
| ROIC | % | -2.59% | - | ||||||
| Operating margin | % | -1328.7% | - | ||||||
| Gross margin | % | +100.00% | - | ||||||
| FCF/Sales | % | -136074.5% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -69.99% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -9.49 | - | ||||||
| Net Debt/EBITDA | x | 0.43 | - | ||||||
| EBIT/Net interest | x | 0.00 | - | ||||||
| Net debt/market cap | % | 0.00% | - | ||||||
| Net debt/Equity | x | -2.43 | - | ||||||
| Gross debt/equity | x | 0.39 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Inovio Pharmaceuticals, Inc. (INO)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free